Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells in vitro

Anti-Cancer Drugs

Volumn 7, Issue 8, 1996, Pages 851-857

  Clements, Mark K ^a   Wasi, Safia ^b   Daoud, Sayed S ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

breast cancer; camptothecin; cleavable complexes; DNA topoisomerase I; endothelial cells

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

EID: 0029729488     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199611000-00006     Document Type: Article

References (30)

1. Daoud SS, Fetouh MI, Giovanella BC. Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts. Anti-Cancer Drugs 1995; 6: 83-93
2. Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88: 3888.
3. Gottlieb JA, Guarino AM, Call JB, et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 1970; 54:461 70.
4. Muggia FM, Creaven PJ, Hansen HH, et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972; 56: 515 21.
5. Moertel CG, Schutt AJ, Reitemeier RJ, et al. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972; 56: 95-101.
6. Hsiang YH, Liu LE Identification of mammalian DNA topoisomerase 1 as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988; 48: 1722-6.
7. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisonierase I - targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046-8.
8. Hsiang YH, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-8.
9. Porter SE, Champoux JJ. The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res 1989; 17: 8521-32.
10. Kaufmann WK, Boyer JC, Estabrooks LL, et al. Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes. Mol Cell Biol 1991; 11: 3711-8.
11. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-82.
12. Zhang H, P DA, Liu LE A model for tumor cell killing by topoisomerase poisons. Cancer Cells 1990; 2: 23-7.
13. Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989; 32: 715-20.
14. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647-56.
15. Blaney SM, Balis FM, Cole DE, et al. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993; 53: 1032-6.
16. Kantarjian HM, Beran M, Ellis A, et al. Phase I study of Topotecan, a new topoisomerase 1 inhibitor, in patients with refractory or relapsed acute leukemia. Blood 1993; 81: 1146-51.
17. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10: 1225-9.
18. Lynch TJ Jr, Kalish L, Strauss G, et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12: 347-52.
19. Pantazis P, Hinz HR, Mendoza JT, et al. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 1992; 52: 3980-7.
20. Wall ME, Wani MC, Natschke SM, et al. Plant antitumor agents. 22. Isolation of 11-hydroxycamptothecin from Camptotheca acuminata Decne: total synthesis and biological activity. J Med Chem 1986; 29: 1553-5.
21. Wani MC, Nicholas AW, Manikumar G, et al. Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. J Med Chem 1987; 30: 1774-9.
22. Potmesil M, Hsiang YH, Lin LF, et al. Resistance of human leukemic and normal lymphocytes to druginduced DNA cleavage and low levels of DNA topoisomerase 11 [published erratum appears in Cancer Res 1988; 48: 4716]. Cancer Res 1988; 48: 3537-43.
23. Pommier Y, Kerrigan D, Hartman KD. et al. Role of calf thymus DNA-topoisomerase I phosphorylation on relaxation activity expression and on DNA protein interaction. Role of DNA-topoisomerase 1 phosphorylation. Mol Biol Rep 1990; 14: 35-9.
24. Jones CB, Clements MK, Wasi S, et al. Sensitivity to camptothecin of human breast cancer cell lines and normal bovine endothelial cells in vitro. Proc Am Ass Cancer Res 1996; 37: 2956.
25. Goldwasser F, Bae I, Valenti M. et al. Topoisonierase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 1995; 55: 2116-21.
26. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994; 14: 1815-23.
27. Harris CC. 1995 Deichmann Lecture - p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. Toxicol Lett 1995; 83: 1-7.
28. Daoud SS, Juliano RL. In vitro effect of liposomeincorporated valinomycin on growth and macromolecular synthesis of normal and ras-transformed 3T3 cells. Cancer Chemother Pharmacol 1989; 23: 151-5.
29. Daoud SS, Fetouh MI, Giovanella BC. Multilamelar liposomes as a delivery system for camptothecin and 9-aminocamtothecin. Proc Am Ass Cancer Res 1993; 37: 2957.
30. Daoud SS, Forde HN. Synergistic cytotoxic actions of cisplatin and liposomal valinomycin on ovarian carcinoma cells. Cancer Chemother Pharmacol 1991; 28: 370-6.